To explore the mechanism of action of Irpex lacteus treatment of hyperuricemia from the perspective of network pharmacology

Abstract Objective: To explore the active ingredients and mechanism of Irpex lacteus against HUA (hyperuricemia) by using network pharmacology and molecular docking technology. Methods: Through literature search and collection, drug-like screening, target prediction, construct a target library of chemical components related to Irpex lacteus; search and construct HUA disease target library through disease database. The PPI network of the crossover gene between the components of Irpex lacteus and HUA was constructed using STRING and Cytoscape; the GO function enrichment analysis of the crossover genes and the enrichment analysis of the KEGG signaling pathway were realized through the Metascape database; the purpose of the “target-signal pathway” network was to analyze its specific mechanism of action; molecular docking to verify the binding ability of the main active ingredients and key targets. Results: 56 active ingredients were screened, the core target of PPI network mitogen-activated protein kinase 3(MAPK3), mitogen-activated protein kinase ’(Mitogen-activated protein kinase 1, MAPK1), etc.; involved 1387 GO biological processes, 48 cell components, and 113 molecular functions; signaling pathway involved AGE-RAGE signaling pathway in diabetes complications, PI3K-Akt signaling pathway, IL-17 signaling pathway, etc; molecular docking results show that the core component tremutins A/C/E had good docking activity with each target. Conclusion: The related products of Irpex lacteus can treat HUA through multiple components, multiple targets, and multiple pathways, which could provide reference for further research and development.